α-synuclein

Latest Series A3 financing includes Labcorp, along with new and longtime investors SCOTTSDALE, Ariz., May 1, 2025 /PRNewswire/ -- CND Life Sciences, Inc. (CND) announced today that it has raised $13.5 million in its Series A equity financing round, with $8.6 million in its most recent Series A3 offering. The company's strong growth has been fueled by its innovative Syn-One Test® that uses skin biopsy tissue to detect and quantify the abnormal form of the alpha-synuclein protein, a known pathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy and other related disorders. Continue Reading CND Life Sciences closes $13.5M Series A equity financing round to continue neurodiagnostics growth and innovation. Post this (PRNewsfoto/CND Life Sciences) "This is a defining time for the neurodegeneration field," said Richard J. Morello, CND's chief executive officer. "CND uses proven technology to help clinicians diagnose diseases like Parkinson's earlier and more precisely than ever before, while collaborating with biopharmaceutical companies to improve the chances for successful clinical trials for novel therapies. We are grateful for the significant support of our mission by many dedicated investors." CND launched its Syn-One Test in late 2019, which has been used by nearly 3,000 neurologists and other clinicians to aid in the diagnosis of synuclein-associated disorders like PD for more than 35,000 patients. In 2024, CND published a key study in the Journal of the American Medical Association demonstrating Syn-One's 95.5% sensitivity overall in detecting abnormal synuclein in patients with different synuclein-associated diseases. Additionally, Syn-One Biomarker Technology™, which leverages CND's AI-assisted platform NerValence™ to quantify the amount of synuclein detected in cutaneous nerves, is being applied in multiple pharmaceutical clinical trials with the hope of measuring an investigational drug's effect on the pathological protein. "Without accurate diagnosis and objective measures of disease progression and therapy response, treatment of the synuclein-related disorders will be hampered," said Christopher Gibbons, MD, chief scientific officer of CND. "Using our proprietary technology, we are able to support a more precise diagnosis and provide convenient, reproducible measures of disease progression and severity in PD, DLB and other synucleinopathies. These advancements offer real opportunities to deliver more effective patient care and accelerate development of disease-modifying therapies." CND's latest Series A3 round included funding from existing investor groups Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital and BlueStone Ventures and from new investors Labcorp, a global leader of innovative and comprehensive laboratory services, MBX Capital and Vilas Ventures. "We are excited to support CND's mission to scale access to their Syn-One Test as part of our deep commitment to help deliver innovative neurology tests and treatments," said Megann Vaughn Watters, Labcorp's vice president of New Ventures & Strategic Alliances. "We are encouraged by the strong adoption of CND's innovative testing that is providing actionable information to ordering clinicians and closing gaps in care for patients facing neurodegenerative diseases." About CND Life Sciences CND Life Sciences supports the care of patients facing the potential diagnosis of neurodegenerative disease and other neurological conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure and REM sleep behavior disorder. Syn-One uses proprietary immunofluorescence techniques to detect, visualize and quantify phosphorylated alpha-synuclein in cutaneous nerves. Results of a prospective, multicenter NIH-sponsored study of the Syn-One Test were published in the Journal of the American Medical Association (JAMA) in 2024 demonstrating >95% sensitivity overall in patients with a clinically determined synucleinopathy.1 The test analyzes three small skin biopsy samples collected in a clinician's office through an in-office patient procedure and includes an assessment of intraepidermal nerve fiber density and other important pathologic markers. Nearly 3,000 neurologists and other clinicians in 50 states have used the Syn-One Test to support their diagnostic evaluation of patients. The company also collaborates with biopharmaceutical companies on clinical trials for investigational therapies targeting neurodegenerative diseases and is conducting studies assessing the test's ability to provide early disease detection and prognostic insights. For more information, visit cndlifesciences.com or connect with us on LinkedIn. 1Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792. Media Contact: Jaryd Leady (856) 803-7855 [email protected] Company Contact: Kathryn Van Wie SVP, Commercial Strategy & Market Development [email protected] SOURCE CND Life Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW HAVEN, Conn., April 30, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a pioneer in advanced research imaging, radiopharmaceutical services, and medical imaging technology, proudly announces the launch of the **NX PET Camera**, a breakthrough in positron emission tomography (PET) imaging designed to accelerate research into critical biomarkers for Parkinson's disease. The **NX PET Camera** offers cutting-edge imaging capabilities, providing researchers with unparalleled precision in detecting and tracking neurodegenerative biomarkers. With **high-resolution PET imaging**, **advanced AI-driven data analysis**, and **enhanced biomarker mapping**, the NX PET Camera is set to revolutionize the study of Parkinson's disease progression and therapeutic response. "Early and accurate biomarker detection is key to advancing our understanding and treatment of Parkinson's disease," said Gilles Tamagnan, CEO of XingImaging. "The NX PET Camera delivers the next-generation imaging technology needed to support groundbreaking research and improve patient outcomes." The Michael J. Fox Foundation for Parkinson's Research (MJFF) funded XingImaging researchers with an aim to use PET imaging to visualize changes in the dopamine pathway of the brain to collect data about PD. Jamie Eberling, PhD, senior vice president of research resources at MJFF, said of the camera's launch, "There's been monumental progress in the last few years through strong investments in finding tracers that can show us alpha-synuclein and other targets in the living brain. This high-resolution PET imaging technology magnifies the impact of these tracers by improving what we can see in real-time. The field is energized by the latest milestones in imaging getting us closer to a day where we can clearly measure, quantify and visualize brain pathology in Parkinson's disease." The NeuroExplorer PET camera from United Imaging is a next-generation ultra-high performance human brain PET imager scanner offering unparalleled resolution (1.4 mm FWHM) and sensitivity (46 kcps/MBq) in the study of brain function. This promises to be revolutionary for imaging of neurodegenerative diseases, like Parkinson's & Alzheimer's, and psychiatric diseases enabling high signal to noise imaging even for small brain structures. XingImaging's NeuroExplorer PET camera enhances the company's delivery of the highest quality science for its research and drug development partners. Key Features of the NX PET Camera: **Ultra-High-Resolution Imaging**: Enables precise visualization of neurodegenerative biomarkers. **AI-Powered Data Analysis**: Advanced machine learning algorithms enhance image interpretation and diagnostic accuracy. **Dynamic Biomarker Mapping**: Provides real-time insights into brain activity and disease progression. **Non-Invasive & Efficient**: Minimizes patient discomfort while delivering rapid, high-quality results. About XingImaging XingImaging is a pioneer in medical imaging technology, committed to advancing healthcare research through innovative solutions. By developing state-of-the-art imaging systems, the company supports researchers and clinicians in their mission to improve XingImaging, a subsidiary of MITRO, is a leading provider of advanced research imaging and radiopharmaceutical services. With a firm focus on quality and innovation, the company offers comprehensive clinical trial imaging services, core lab services, and radiotracer manufacturing. By maintaining the highest industry standards, XingImaging partners with research pharmaceutical and biotech organizations to drive breakthroughs in medical diagnostics and treatment diagnostic accuracy and therapeutic outcomes for neurological diseases. About MITRO MITRO is a molecular imaging contract research organization (MI-CRO) company in China. MITRO provides outstanding contract research for new drug development using radiolabeling and molecular imaging techniques. MITRO merged with XingImaging in 2023 to create one company dedicated to providing a full spectrum of CRO & CDMO research service offerings. New Haven Facility Our New Haven facility offers a comprehensive range of services, including: Clinical Trial Services: State-of-the-art Clinic providing consistent, compassionate, and high-quality services to research participants to support clinical trials. Advanced Imaging Services: Advanced imaging technologies designed and implemented with an emphasis on precision and quality, including PET and SPECT. Radiotracer Manufacturing: Tailored GMP production to meet the precise needs of clinical trials with stringent quality control. Leading Imaging Analysis Services: Tailored analysis pipelines that focus on maximizing signal-to-noise, robustness and reproducibility. XingImaging's commitment to excellence is reflected in every aspect of the new facility's operations, ensuring that participants, sponsors, and collaborators receive the highest quality of service. The NX PET Camera is now available for research institutions, hospitals, and pharmaceutical partners aiming to accelerate biomarker discovery and drug development for Parkinson's disease and other neurodegenerative disorders. SOURCE XingImaging, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY. Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+ Presenter: Joanne Taylor, Ph.D., Senior Vice President of Research, Gain Therapeutics Session: Oral Poster Presentation – Guided Poster TourSession Date: Saturday, May 10, 2025Session Time: 8:00-9:00 a.m. EST About GT-02287Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting. Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with a >50% increase in glucocerebrosidase (GCase) activity among those receiving GT-02287 at clinically relevant doses. GT-02287 is currently being evaluated in a Phase 1b clinical trial for the treatment of Parkinson’s disease with or without a GBA1 mutation. The primary endpoint of the trial, which is currently enrolling participants across 7 sites in Australia, is to evaluate the safety and tolerability of GT-02287 after 3 months of dosing in people with Parkinson’s disease. Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. Forward-Looking StatementsThis release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Investors:Gain Therapeutics, Inc. Apaar Jammu Manager, Investor Relations and Public Relationsajammu@gaintherapeutics.com LifeSci Advisors LLCChuck PadalaManaging Directorchuck@lifesciadvisors.com Media:Russo Partners LLC Nic Johnson and Elio Ambrosionic.johnson@russopartnersllc.comelio.ambrosio@russopartnersllc.com(760) 846-9256